2023 Guidance and Q3 Earnings

HIV: 15% growth in Q3 primarily driven by oral 2DR and long-acting regimens Strong execution across HIV oral 2DR and long-acting regimens portfolio Sales £m 1000 60% 53% 51% 46% 47% 50% 42% 39% 36% 33% 600 28% 25% 26% 800 400 200 0 ΟΙ 2021 Dovato Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2021 2021 2022 2022 2022 2022 2023 2023 2023 Cabenuva Juluca Apretude 40% 30% 20% 10% 0% Oral 2DR & LA Oral 2DR & LA sales as a % of total HIV sales Growth driven by oral 2DR and long-acting regimens . • • • • Sales: £1.6bn in Q3 with all regions driving growth FY 2023: Growth outlook upgraded to circa 10% Dovato: £477m - leading oral 2-drug regimen Dolutegravir: Paediatric exclusivity confirmed in US Cabenuva: £182m - increasing HCP confidence, new SOLAR data. Regimen approved in China Apretude: £37m - EU approval granted in September 2023 Pipeline: target dosing intervals for LA regimens extended to every four months in treatment and prevention with roadmap to reach every six months by end of decade GSK 1. Two drug regimen 19

View entire presentation